Comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 Diabetes

Diabetes Care

Volumn 32, Issue 1, 2009, Pages 32-37

  Floch, Jean Pierre Le ^a   Lévy, Marc ^b   Helen, Mosnier Pudar ^c   Nobels, Frank ^d   Laroche, Sylvie ^e   Gonbert, Sophie ^e   Eschwege, Eveline ^f   Fontaine, Pierre ^g  

^a Medical Clinic   (France)

^b Max Fourestier Hospital   (France)

^c Institut Cochin   (France)

^d OL Vrouwziekenhuis Hospital   (Belgium)

^e NOVO NORDISK A S   (Denmark)

^f INSERM   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; EATING; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN ASPART; INSULIN, LONG-ACTING; TREATMENT OUTCOME;

EID: 64549093838     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0332     Document Type: Article

References (18)

1. Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, Kurtzhals P: The mechanism of protraction of insulin det-emir, a long-acting, acylated analog of human insulin. Pharm Res 21:1498-1504, 2004
2. Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR: A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28:1107-1112, 2005
3. Kurtzhals P: How to achieve a predictable basal insulin? Diabetes Metab 31(4 Pt 2): 4S25-4S33, 2005
4. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614-1620, 2004
5. Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F,RønnB, Zdravk-ovic M, Pieber TR: Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 115:461-467, 2007
6. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T: Albumin-bound basal insulin analogs (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 di- abetes. Diabetes Obes Metab 9:290 -299, 2007
7. Heise T, Pieber TR: Towards peakless, reproducible and long-acting insulins: an assessment of the basal analogs based on isoglycemic clamp studies. Diabetes Obes Metab 9:648-659, 2007
8. Home P, Kurtzhals P: Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 7:325-343, 2006
9. Hermansen K, Davies M: Does insulin de-temir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9:209-217, 2007
10. Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L: Safety and efficacy of insulin det-emir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 61:523-528, 2007
11. DeVries JH, Nattrass M, Pieber TR: Refining basal insulin therapy: what have we learned in the age of analogs? Diabetes Metab Res Rev 23:441-454, 2007
12. Tsou HH, Hsiao CF, Chow SC, Yue L, Xu Y, Lee S: Mixed noninferiority margin and statistical tests in active controlled trials. J Biopharm Stat 17:339-357, 2007
13. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J: Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 24:27-34, 2007
14. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J: Effects of OD insulin detemir or neutral protamin hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus insulin regimen. Clin Ther 26:724 -736, 2004
15. Albright ES, Desmond R, Bell DS: Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injec- tions of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 27:632-633, 2004
16. Ashwell SG, Gebbie J, Home PD: Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times. Diabet Med 23:46-52, 2006
17. Ashwell SG, Gebbie J, Home PD: Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med 23:879-886, 2006
18. Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase PH: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 66:49 -56, 2004